Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy

Sirohi, Bhawna; Powles, R; Cavanagh, Jamie; Oakervee, Heather; Dyer, Philip D.; Rintala, T.; Kulkarni, Samar; Rudin, C.; Horton, C; Treleaven, J; Morgan, Gareth J.

doi:10.1080/10245330601111631

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also possible to collect stem cells successfully without pretransplantation cytoreduction. 12 However, all these data are from the era before the introduction of novel agents. Induction therapies were primarily corticosteroid based, such as doxorubicin, dexamethasone, and vincristine; doxorubicinmethylprednisolone; or the combination of cyclophosphamide, vincristine, doxorubicin, and methylprednisolone.…”

Section: Introductionmentioning

confidence: 99%

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction

Gertz

Kumar

Lacy

et al. 2010

Blood

View full text Add to dashboard Cite

Autologous stem cell transplantation as a platform for multiple myeloma treatment is the standard of care for patients who can safely withstand the procedure. Before novel agents were introduced, onethird to one-half of patients did not achieve partial response at transplantation. Previous medical literature has shown that in this past era, absence of initial response to induction therapy had no impact on progression-free survival and overall survival after highdose therapy. Lack of response to initial induction did not preclude a good response after stem cell transplantation. With the introduction of novel agentsimmunomodulatory drugs and proteasome inhibitors-response rates with initial therapy are now between 70% and 100%. This retrospective study analyzes progression-free survival and overall survival in patients who do not have a partial response (never responded or progressed during continuous therapy) after induction therapy with a regimen that contains thalidomide or lenalidomide. Unlike patients in reports published previously-before immunomodulatory drugs-patients who do not achieve partial remission have a significantly shorter overall survival from transplantation (73.5 vs 30.4 months) and a shorter progression-free survival (22.1 vs 13.1 months; P < .001). Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy. (Blood. 2010;115:2348-2353)

show abstract

Section: Introductionmentioning

confidence: 99%

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction

Gertz

Kumar

Lacy

et al. 2010

Blood

View full text Add to dashboard Cite

show abstract

Current Awareness in Hematological Oncology

2008

Hematological Oncology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Reviews; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non‐Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen

McKibbin

Burzynski

Greene

et al. 2007

Leukemia & Lymphoma

View full text Add to dashboard Cite

Paclitaxel and G-CSF have been evaluated for HPC mobilization in breast cancer and found to have tolerable toxicity with a predictable time to initiate leukapheresis. However, this approach has not been reported in patients with hematologic malignancies failing prior mobilization. We report a case-series of 26 adults given paclitaxel and G-CSF for HPC mobilization after failure of an initial mobilization. Patients received paclitaxel 250 mg/m(2) followed by G-CSF 10-16 mcg/kg/day. Compared to the initial regimen, paclitaxel mobilization produced greater CD34+ cell yields (median 1.53 x 10(6) CD34+ cells/kg vs. 0.79 x 10(6) CD34+ cells/kg, p = 0.004). Seventy-six percent of patients initiated leukapheresis on day 8, the remainder on day 9 or 10. Three patients developed febrile neutropenia resulting in one death prior to leukapheresis. Overall, 73% of patients proceeded with autologous HPC transplant. This case-series suggests paclitaxel may be an option for HPC mobilization in patients failing prior regimens.

show abstract

Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy

Cited by 3 publications

References 9 publications

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction

Current Awareness in Hematological Oncology

Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen

Contact Info

Product

Resources

About